BlackBio signs JV agreement in India to develop, manufacture and commercialize new integral solutions for diagnostics
2B BlackBio, S.L. has signed with its local partner in India, Kilpest Ltd an agreement to participate in the `recently established joint venture between Kilpest and Biotools B&M Labs, S.A., renamed now as 3B BlackBio Biotech India Ltd´. With this agreement the new JV with laboratories in Bhopal, and Headquarters in Mumbai, India, will manufacture and develop integral solutions in the area of Personalized medicine and will offer diagnostic tests to predict drug treatment effectiveness (Companion Diagnostics), providing technologies to participate in the present exponential development of the Indian Pharma sector.
Together with a network of local Pharma companies, hospitals and clinical labs, the new Joint Venture will introduce into India an innovative site‐directed microsequencing platform that combines ease of use, specifity and cost competitiveness, allowing the introduction of companion diagnostics to one of the biggest global Healthcare markets.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.